Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
about
Off-label use of targeted therapies in oncologyPragmatic medicine in solid cancer: a translational alternative to precision medicineDrug Pricing Evolution in Hepatitis CChallenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer.Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life.Getting Past No in Cancer Care.Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven TherapiesVariation of Cost among Anti-cancer Drugs Available in Indian Market.Buying cures versus renting health: Financing health care with consumer loans.Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.The high price of anticancer drugs: origins, implications, barriers, solutions.The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy.Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.Linking the Price of Cancer Drug Treatments to Their Clinical Value.Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States.Financial Toxicity of Cancer Care: It's Time to Intervene.Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of BenefitsThe Value of Considering Cost, and the Cost of Not Considering ValueAdaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Integrins as Therapeutic Targets: Successes and Cancers.An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials.Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions.Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward.Ten Principles to Guide Health Reform.The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Hans Christian Andersen and the Value of New Cancer Treatments.Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.Dealing with the spiralling price of medicines: issues and solutions.Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.Budget impact and cost-effectiveness: can we afford precision medicine in oncology?Combining drugs and extending treatment - a PFS end point is not sufficient.Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
P2860
Q26747685-AB02A1DC-D6BA-4618-B474-D9F815FCC458Q28391863-C1187618-F57D-4920-A0F9-6407ABA0EC55Q28550311-BA09B260-ABA7-40CE-839C-8A6D2E198AC1Q30490454-9F588FB5-349A-4C3B-9208-D029C8D8B449Q36923839-9CE37879-901C-4A37-A567-6549DD86F47FQ37091161-24A598C7-D09A-48EB-8D1C-A76892E7B6B3Q37242372-18D3C69A-EEA2-4DE4-9A7B-CADFFC494EE0Q37543021-546FD13F-71D4-45E3-B588-2614535F2131Q38749220-2E2F57DC-706C-4E31-848E-D7D3FFFF318CQ38810189-CCD78263-EAEB-49C3-9968-06F7748F9A2DQ38848793-EB430EB4-77F2-47A2-87DE-0D8632EEDAC9Q38908352-650F1B67-DCB2-4095-8A89-590283975A38Q38909657-474A2DBE-811E-4EA2-A030-CC40673DD16DQ39241834-32FD8602-ED61-49FB-9502-76D82119E519Q39270072-A1195386-79D6-42D9-B15A-AF909B59CDA7Q39431314-14433E71-F245-4D67-8A5E-1DA7D1EC4516Q39622830-87FDBDDD-1602-4A2F-8F18-39AF0BB8BCA8Q39787879-46792637-B79D-4B94-B6AD-478E49CE80D6Q40149586-A3A758A7-A16B-45FB-B7CE-432FA4108B12Q40327176-6CC61243-B4F1-45BA-BC09-8EF87874CC5FQ41058870-8AE78262-0C97-48A7-A651-042B1D40A1D6Q41491267-BC39F2C2-D37D-414F-AB00-CE32A67F024CQ41508374-925CFF51-8102-4F41-9D27-9C4244C656CBQ41526451-7DD6BFB1-5D4F-4A81-8D84-F0284A339FCDQ41670949-B6A67688-5476-4396-A8D1-61CD09AEEA72Q42269831-B45F81A1-646A-4B75-9E54-E29360319AECQ42319245-C2B769FF-442E-4175-9AAB-A814A994F861Q42355446-DBE752B5-3401-4D3C-A76B-FA00102F8A8AQ48046108-B4B31F8A-5E7C-4279-B72A-546BFC28A2C1Q48234920-3F334E70-7E1D-4F7C-8597-6577C7E2155FQ49315568-FF509653-113C-48AA-A714-397FA39B0AFDQ49824552-17C3013F-1175-4E90-876E-7610A1D33FB9Q50001044-FB2F5E85-C4F8-481A-8732-E244EB572446Q50080930-DEF293EA-E624-4506-B675-077308407388Q52668760-0E897353-2C8F-4260-9E5A-DFA9DA588A25Q52990848-6E61E2D9-51BD-4852-ACB9-60A67B2DCA25Q53110057-82A3B866-A613-4944-8B44-5EC8DAA3528AQ54977541-D0EBDF76-9279-4CAB-A48F-D4A5113A4483Q55069013-E04F514B-2447-4D92-8564-734BCF77B361Q55224120-E2E0D2A6-3EE7-470F-B8DE-F348EF09E05C
P2860
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@en
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@nl
type
label
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@en
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@nl
prefLabel
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@en
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@nl
P1433
P1476
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
@en
P2093
Sham Mailankody
P304
P356
10.1001/JAMAONCOL.2015.0373
P50
P577
2015-07-01T00:00:00Z